Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 23 studies | 28% ± 12% | |
CD16-positive, CD56-dim natural killer cell, human | 12 studies | 38% ± 17% | |
mature NK T cell | 10 studies | 24% ± 9% | |
CD16-negative, CD56-bright natural killer cell, human | 7 studies | 24% ± 5% | |
CD8-positive, alpha-beta T cell | 5 studies | 25% ± 7% | |
gamma-delta T cell | 5 studies | 24% ± 2% |
Insufficient scRNA-seq data for expression of TBX21 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 415.00 | 578 / 578 | 65% | 2.35 | 755 / 1155 |
thymus | 94% | 96.15 | 611 / 653 | 48% | 1.41 | 291 / 605 |
kidney | 72% | 63.16 | 64 / 89 | 67% | 2.15 | 600 / 901 |
uterus | 78% | 45.93 | 132 / 170 | 51% | 1.68 | 235 / 459 |
stomach | 86% | 65.73 | 310 / 359 | 41% | 1.04 | 118 / 286 |
breast | 76% | 53.73 | 349 / 459 | 51% | 1.64 | 565 / 1118 |
liver | 91% | 79.89 | 205 / 226 | 32% | 0.76 | 129 / 406 |
bladder | 76% | 77.67 | 16 / 21 | 31% | 1.03 | 156 / 504 |
prostate | 83% | 61.09 | 204 / 245 | 23% | 0.44 | 116 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 17.25 | 29 / 29 |
spleen | 100% | 1423.15 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 1901.59 | 925 / 929 | 0% | 0 | 0 / 0 |
intestine | 62% | 76.08 | 603 / 966 | 31% | 0.74 | 164 / 527 |
adipose | 91% | 92.02 | 1096 / 1204 | 0% | 0 | 0 / 0 |
skin | 24% | 23.91 | 443 / 1809 | 58% | 2.97 | 274 / 472 |
esophagus | 52% | 23.39 | 751 / 1445 | 30% | 0.65 | 55 / 183 |
tonsil | 0% | 0 | 0 / 0 | 80% | 3.66 | 36 / 45 |
pancreas | 18% | 6.62 | 58 / 328 | 45% | 1.19 | 80 / 178 |
adrenal gland | 39% | 16.19 | 100 / 258 | 10% | 0.29 | 22 / 230 |
ovary | 27% | 13.56 | 49 / 180 | 21% | 0.38 | 89 / 430 |
heart | 46% | 23.03 | 394 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 43% | 30.82 | 580 / 1335 | 0% | 0 | 0 / 0 |
brain | 13% | 5.42 | 348 / 2642 | 12% | 0.35 | 86 / 705 |
muscle | 11% | 4.37 | 91 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 11% | 0.38 | 9 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0072676 | Biological process | lymphocyte migration |
GO_2000556 | Biological process | positive regulation of T-helper 1 cell cytokine production |
GO_0001708 | Biological process | cell fate specification |
GO_0045580 | Biological process | regulation of T cell differentiation |
GO_0032703 | Biological process | negative regulation of interleukin-2 production |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0009615 | Biological process | response to virus |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_2000552 | Biological process | negative regulation of T-helper 2 cell cytokine production |
GO_0002296 | Biological process | T-helper 1 cell lineage commitment |
GO_2000320 | Biological process | negative regulation of T-helper 17 cell differentiation |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0048304 | Biological process | positive regulation of isotype switching to IgG isotypes |
GO_2000329 | Biological process | negative regulation of T-helper 17 cell lineage commitment |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0043025 | Cellular component | neuronal cell body |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TBX21 |
Protein name | T-box transcription factor TBX21 (T-box protein 21) (T-cell-specific T-box transcription factor T-bet) (Transcription factor TBLYM) |
Synonyms | TBLYM TBET |
Description | FUNCTION: Lineage-defining transcription factor which initiates Th1 lineage development from naive Th precursor cells both by activating Th1 genetic programs and by repressing the opposing Th2 and Th17 genetic programs . Activates transcription of a set of genes important for Th1 cell function, including those encoding IFN-gamma and the chemokine receptor CXCR3. Induces permissive chromatin accessibilty and CpG methylation in IFNG . Activates IFNG and CXCR3 genes in part by recruiting chromatin remodeling complexes including KDM6B, a SMARCA4-containing SWI/SNF-complex, and an H3K4me2-methyltransferase complex to their promoters and all of these complexes serve to establish a more permissive chromatin state conducive with transcriptional activation (By similarity). Can activate Th1 genes also via recruitment of Mediator complex and P-TEFb (composed of CDK9 and CCNT1/cyclin-T1) in the form of the super elongation complex (SEC) to super-enhancers and associated genes in activated Th1 cells . Inhibits the Th17 cell lineage commitment by blocking RUNX1-mediated transactivation of Th17 cell-specific transcriptinal regulator RORC. Inhibits the Th2 cell lineage commitment by suppressing the production of Th2 cytokines, such as IL-4, IL-5, and IL- 13, via repression of transcriptional regulators GATA3 and NFATC2. Protects Th1 cells from amplifying aberrant type-I IFN response in an IFN-gamma abundant microenvironment by acting as a repressor of type-I IFN transcription factors and type-I IFN-stimulated genes. Acts as a regulator of antiviral B-cell responses; controls chronic viral infection by promoting the antiviral antibody IgG2a isotype switching and via regulation of a broad antiviral gene expression program (By similarity). Required for the correct development of natural killer (NK) and mucosal-associated invariant T (MAIT) cells . . |
Accessions | Q9UL17 ENST00000177694.2 |